Clinical trial · Observational
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone (SVd) for the Treatment of Multiple Myeloma Patients
NCT06933277CI-TRIAL-00094868recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- SdV therapy effectiveness in terms of Progression Free Survival
- timeFrame
- at 12 months
- description
- to describe the effectiveness of the use of SVd therapy outside clinical trials in terms of Progression free survival after 12 months from the start of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age equal to or greater than 18 years old at the time of SVd initiation * Signed informed consent (if applicable). * Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria. * Relapse after one to three lines of therapy. * Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization) * Prior treatment with and refractoriness to lenalidomide. Exclusion Criteria: \- Previous exposure to selinexor.
References
Publications (0)
Data not yet available
No reference posted for this study.